CN110283162A - A kind of novel epidermal growth factor receptor inhibitor and its application - Google Patents
A kind of novel epidermal growth factor receptor inhibitor and its application Download PDFInfo
- Publication number
- CN110283162A CN110283162A CN201910613192.6A CN201910613192A CN110283162A CN 110283162 A CN110283162 A CN 110283162A CN 201910613192 A CN201910613192 A CN 201910613192A CN 110283162 A CN110283162 A CN 110283162A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- reaction
- added
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001301 EGF receptor Human genes 0.000 title claims abstract description 10
- 108060006698 EGF receptor Proteins 0.000 title claims abstract description 9
- 239000003112 inhibitor Substances 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 229940002612 prodrug Drugs 0.000 claims abstract description 10
- 239000000651 prodrug Substances 0.000 claims abstract description 10
- 239000012453 solvate Substances 0.000 claims abstract description 10
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 11
- 150000003246 quinazolines Chemical class 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 claims description 8
- 150000003230 pyrimidines Chemical class 0.000 claims description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 229910052760 oxygen Chemical group 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 quinazoline compound Chemical class 0.000 claims 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 35
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract description 22
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract description 22
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 3
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 50
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 32
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 26
- 238000000926 separation method Methods 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 24
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 24
- 235000017557 sodium bicarbonate Nutrition 0.000 description 24
- 238000005406 washing Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000001035 drying Methods 0.000 description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 229910001873 dinitrogen Inorganic materials 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 235000002597 Solanum melongena Nutrition 0.000 description 10
- 244000061458 Solanum melongena Species 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 229960003278 osimertinib Drugs 0.000 description 5
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229940121647 egfr inhibitor Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ZKJKXGCLZUMGNT-UHFFFAOYSA-N methanesulfonic acid;piperazine Chemical compound CS(O)(=O)=O.C1CNCCN1 ZKJKXGCLZUMGNT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of novel epidermal growth factor receptor inhibitors and its application.Miazines, pyrido [2 shown in logical formula (I), 3-d] miazines, quinazoline compounds and its pharmaceutically acceptable salt, prodrug or solvate be the inhibited compound of tumour cell that a kind of pair of EGFR tyrosine kinase generates variation, it can be used for the treatment of kinds cancer, combination therapy, or prevention.More particularly such compound is significant to the variation type therapeutic effect of del19, L858R, T790M and C797S of EGFR.
Description
Technical Field
The invention discloses a derivative taking pyrimidines, pyrido [2,3-d ] pyrimidines and quinazolines as parent nucleus, and pharmaceutically acceptable salt, prodrug and solvate thereof, and a preparation method and medical application thereof, and the derivative is a compound which has an inhibitory effect on tumor cells generating variation of EGFR tyrosine kinase, and can be used for treating, combining and preventing various cancers. More particularly, the compounds have obvious treatment effect on the del19, L858R, T790M and C797S variant types of EGFR.
Background
Malignant tumors, as the biggest public health problem in the world, are common diseases and frequently encountered diseases that seriously threaten human health. Research shows that EGFR has over-expression in various tumors and plays an important role in cell proliferation, so that EGFR is one of the potential antitumor drug targets. In recent years, dry-to-drug development for EGFR has achieved encouraging performance. The first generation of EGFR inhibitors Gefitinib, Erlotinib, Icotininib and the second generation of EGFR inhibitors Afatinib which take EGFR as a target have been approved for clinical treatment of non-small cell lung cancer.
EGFR (also known as ErbB1 or HER1) is part of the ErbB family of transmembrane receptor tyrosine kinases that primarily regulate signaling pathways for cell amplification and apoptosis. EGFR structurally consists of an extracellular ligand binding region, a single-chain transmembrane region, and an intracellular protein tyrosine kinase region. It is widely present on epithelial cell membranes except vascular tissues, and is overexpressed in various human malignant tumors, particularly in solid tumors such as lung cancer, gastric cancer, cervical cancer, pancreatic cancer, renal cancer, breast cancer and the like.
The representative drug of the third generation EGFR-TKI is Osimetinib (AZD-9291), the molecule can be combined with Cys-797 residue in an ATP binding site of EGFR kinase in an irreversible covalent bond mode, so that the drug resistance of the first two generations of drugs is overcome, and the EGFR-TKI has excellent inhibitory activity on L858R mutant tumor cells, exon 19 deletion tumor cells and T790M mutant tumor cells. Unlike the first and second generations, the activity of the mutant EGFR (including the T790M mutation) by the Osimetinib (AZD-9291) is much higher than that of the wild-type EGFR, and higher safety is shown. For patients, the drug reduces toxicity of skin and gastrointestinal tract caused by inhibition of wild-type EGFR, thereby having a wide clinical application prospect.
Unfortunately, clinical data show that after the patient uses the Osimetinib (AZD-9291) for a long time, the exon 20 site of the EGFR of the patient generates a new C797S mutation, so that the treatment effect of the drug is greatly reduced. In vitro studies show that after EGFR kinase is mutated at C797S site, drug molecules cannot form covalent bonds with EGFR kinase, so that the binding capacity of the drug molecules and EGFR kinase is reduced, the inhibitory activity of the drug is further reduced, and drug resistance is generated. How to overcome the problem of drug resistance of the Osimetinib (AZD-9291) caused by the mutation of C797S is a necessary difficulty for developing a new generation of EGFR-TKI.
Disclosure of Invention
The invention discloses a derivative taking pyrimidines, pyrido [2,3-d ] pyrimidines and quinazolines as parent nucleus and pharmaceutically acceptable salt, prodrug and solvate thereof, which is a compound having an inhibiting effect on tumor cells generating variation of EGFR tyrosine kinase and can be used for treating, combining and preventing various cancers. More particularly, the compounds have obvious treatment effect on the variant types of del19, L858R and T790M of EGFR.
The technical scheme adopted by the invention is as follows: pyrimidines, pyrido [2,3-d ] pyrimidines, quinazolines and pharmaceutically acceptable salts, prodrugs or solvates thereof having the general formula (I):
wherein,
R1is composed ofWherein X is selected from one of F, Cl, Br, OH or CN;
R2is composed ofAny one of the above;
R3is any one of hydrogen or oxygen substituted C1-C6 alkyl, CD3 or F substituted C1-C6 alkyl;
R4is composed of
The pyrimidine compounds, pyrido [2,3-d ] pyrimidine compounds and quinazoline compounds represented by the general formula (I) have the following structures.
A composition is prepared by taking the pyrimidine, pyrido [2,3-d ] pyrimidine and quinazoline compounds and pharmaceutically acceptable salts thereof as effective components and combining the effective components with pharmaceutically acceptable carriers.
Further, the pharmaceutically acceptable carrier is selected from one or more of a filler, a disintegrant, a binder and a lubricant.
Further, the composition is prepared into the dosage forms of tablets, capsules, granules, sprays or injections.
The pyrimidine, pyrido [2,3-d ] pyrimidine and quinazoline compounds and pharmaceutically acceptable salts, prodrugs or solvates thereof and the application of the composition as a protein tyrosine kinase inhibitor.
Further, the protein tyrosine kinase inhibitor is an epidermal growth factor receptor inhibitor.
The pyrimidine, pyrido [2,3-d ] pyrimidine and quinazoline compounds, pharmaceutically acceptable salts, prodrugs or solvates thereof and application of the composition in preparing medicines for treating diseases related to epidermal growth factor receptor overexpression.
Further, the diseases related to the overexpression of the epidermal growth factor receptor are selected from renal cancer, lung cancer, prostate cancer, pancreatic cancer, breast cancer and glioma.
The invention has the beneficial effects that: the derivative taking pyrimidines, pyrido [2,3-d ] pyrimidines and quinazolines as a parent nucleus prepared by the invention is a compound with an inhibiting effect on tumor cells generating variation of EGFR tyrosine kinase, and can be used for treating, jointly treating or preventing various cancers. More particularly, the compounds have obvious treatment effect on the variant types of del19, L858R and T790M of EGFR.
Detailed Description
The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and their methods of preparation. It should be understood that the scope of the following examples and preparations are not intended to limit the scope of the invention in any way.
The following synthetic schemes describe the preparation of the pyrimidine derivatives, pyrido [2,3-d ] pyrimidine derivatives and quinazoline derivatives of the general formula (I).
All starting materials are prepared by the means described in the synthetic schemes below, by methods well known to those of ordinary skill in the art of organic chemistry or are commercially available. All of the final derivatives of the invention are prepared by, or by analogy with, the methods described in the synthetic schemes below and are well known to those of ordinary skill in the art of organic chemistry. All variables used in the synthetic routes described below are as defined below or as defined in the claims.
The examples are intended to illustrate, but not to limit, the scope of the invention. NMR of the compounds was measured using BrukeraRx-400 or ARX-600 and Mass Spectroscopy was measured using Agilent 1100 LC/MSD; all reagents used were analytically or chemically pure.
The synthetic route is as follows:
fragment one: synthesized by the following method2The functional groups are shown as groups in the claims:
fragment two: synthesized by the following method5Are the corresponding basic groups.
Fragment three: the target compound is prepared by adopting the following synthesis method.
EXAMPLE 1 preparation of Compound 4
1. Synthesis of intermediate e
Dissolving d (10g, 1.0eq) in acetonitrile (30mL), dropwise adding BOC anhydride (14g, 1.2eq) at 25 ℃, then raising the temperature to 60 ℃, reacting for 10 hours, rotationally evaporating part of solvent, cooling, crystallizing, filtering to obtain a filter cake, and washing the filter cake with acetonitrile solvent to obtain a pure intermediate e. And adding BOC anhydride (8g) into the obtained filtrate to continue the reaction, cooling and crystallizing for the second time after 10 hours, and repeating the operation for 5 times to obtain an intermediate e, wherein 14g of a light yellow solid is obtained, and the yield is 91%.
LC-MS(ESI):m/z 287.10(M+H)+
2. Synthesis of intermediate f
Intermediate e (8.4g, 1eq), pyrrole (2.9g, 1.5eq), sodium hydroxide (2.3g, 2eq) were added to a 100mL eggplant-shaped flask, DMSO (15mL) was added, the reaction time was 4h at 40 ℃ and the reaction was checked by TLC to be complete. And adding water into an eggplant-shaped bottle to separate out insoluble substances, filtering, and washing a filter cake with water to obtain an intermediate f, wherein the red solid is 3.6g, and the yield is 36.8%.
LC-MS(ESI):m/z 334.13(M+H)+
3. Synthesis of intermediate g
The intermediate f (18.29g, 10eq) is dissolved in 1, 4-dioxane, then ferric trichloride (4.45g, 3.0eq) containing six crystal water, activated carbon (400mg, 6eq) and 80% hydrazine hydrate (82g, 300eq) are added, the reaction is carried out for 5h at 110 ℃, and the completion of the reaction is detected by TLC point plates. Then filtered through celite, the aqueous phase extracted with ethyl acetate and spun dry under reduced pressure to give g of intermediate, 15g with 90% yield.
LC-MS(ESI):m/z 304.16(M+H)+
4. Synthesis of intermediate h
Intermediate g (1g, 1eq) was dissolved in tetrahydrofuran (4mL) and N, N-diisopropylethylamine (0.802g, 2.5eq) and acryloyl chloride (0.4g, 2.0eq) were added and reacted at 25 ℃ for 6 h. The reaction was complete by TLC. Excess sodium bicarbonate was added to the reaction solution to quench acryloyl chloride, extracted, washed three times with ethyl acetate, the organic phases were combined, and the intermediate h was spin-dried under reduced pressure with a yield of 1.1g of 93.4%.
LC-MS(ESI):m/z 358.17(M+H)+
5. Synthesis of intermediate i-4
The compound morpholine solution (588mg, 1.5eq), glacial acetic acid (10mL) with 40% formaldehyde content (270mg, 1.5eq) were added to an eggplant type bottle in sequence, stirred at normal temperature for 1h, then the intermediate h (2g, 1.0eq) was added to the eggplant type bottle, stirred at normal temperature, and the reaction was detected to be complete by TLC. And then, evaporating part of the solvent in a rotary manner, adding 100mL of tap water, and filtering to obtain a filter cake, namely the intermediate i-4.
LC-MS(ESI):m/z 457.2(M+H)+
6. Synthesis of intermediate j-4
Intermediate i-4(0.4g, 1.0eq) was dissolved in dichloromethane solution, then trifluoroacetic acid (1.5g, 15eq) was added for 3h and the reaction was complete by TLC. Then sodium bicarbonate is added into the reaction liquid to adjust the pH value to 10, extraction is carried out, ethyl acetate is used for washing for 3 times, organic phases are combined, decompression and spin drying are carried out, column chromatography separation is carried out, and the intermediate j-4 of the product is obtained, wherein the yield of 0.18g is 57%.
LC-MS(ESI):m/z 357.2(M+H)+
7. Synthesis of intermediate c-1
The compound a (5g, 1.0eq), b-1(5g, 0.9eq) and aluminum trichloride (5g, 1.0eq) were added to a 100mL eggplant-shaped flask, reacted at 80 deg.C, the reaction was complete by TLC, then ice water was added, stirred for 5min, filtered with suction, and the cake was rinsed with 50mL water. Column chromatography separation to obtain intermediate c-1, 7g with yield 75.3%
LC-MS(ESI):m/z 244.1(M+H)+
8. Synthesis of Compound 4
C-1(35mg, 1.5eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (48mg, 2eq) and j-4(50mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Adding sodium bicarbonate into the reaction solution to adjust the pH value to 10, extracting, washing twice by dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 4, wherein the yield of 20mg is 24.7%.
LC-MS(ESI):m/z 564.2(M+H)+
1H NMR(600MHz,CDCl3)δ9.47(s,1H),8.96(s,1H),8.76(s,1H),8.42(d,J=5.2Hz,1H),8.10(d,J=6.9Hz,1H),7.83(s,1H),7.40(d,J=7.3Hz,1H),7.33–7.27(m,3H),7.24(d,J=5.1Hz,1H),6.74(s,2H),6.27(dd,J=39.6,20.2Hz,4H),5.68(d,J=10.2Hz,1H),3.97(s,3H),3.89(s,3H),3.66(d,J=17.6Hz,4H),3.28(d,J=13.9Hz,1H),3.16(d,J=13.8Hz,1H),2.67(s,2H),2.33(s,2H).
EXAMPLE 2 preparation of Compound 5
1. Synthesis of intermediate i-5
Diethylamine solution (0.306g, 1.5eq), 40% formaldehyde content (0.315g, 1.5eq), and glacial acetic acid (10mL) were added sequentially to the eggplant type bottle, stirred at room temperature for 1 hour, then intermediate h (1g, 1eq) was added to the eggplant type bottle, stirred at room temperature, and the reaction was detected by TLC. Then, part of the solvent is removed by rotary evaporation, 100mL of tap water is added, and a filter cake is obtained by filtration, namely the product intermediate i-5, 0.6g, and the yield is 48.5%.
LC-MS(ESI):m/z 443.26(M+H)+
2. Synthesis of intermediate j-5
Intermediate i-5(600mg, 1eq) was dissolved in dichloromethane solution, followed by trifluoroacetic acid (2320mg, 15eq) for 3h, and the reaction was complete as detected by TLC. Adding sodium bicarbonate into the reaction solution to adjust the pH value to 10, extracting, washing with ethyl acetate for 3 times, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain a product intermediate j-5, wherein the yield of 400mg is 86%.
LC-MS(ESI):m/z 344.2(M+H)+
3. Synthesis of Compound 5
C-1(94mg, 1.5eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (110mg, 2eq) and j-5(110mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 5, wherein the yield of 100mg is 62.5%.
LC-MS(ESI):m/z 550.29(M+H)+
1H NMR(600MHz,Chloroform-d)δ10.26(s,1H),9.29(s,1H),8.76(s,1H),8.41(d,J=5.3Hz,1H),8.09(d,J=6.9Hz,1H),7.78(s,1H),7.41–7.38(m,1H),7.28(ddd,J=6.9,4.7,1.5Hz,2H),7.23(d,J=5.3Hz,1H),6.70(d,J=8.7Hz,2H),6.31(dd,J=16.9,1.7Hz,1H),6.22(d,J=4.8Hz,2H),6.10(dd,J=17.0,10.3Hz,1H),5.62(dd,J=10.1,1.7Hz,1H),3.97(s,3H),3.87(s,3H),3.40–3.26(m,2H),2.73(dd,J=13.4,7.1Hz,2H),2.57(dd,J=13.4,7.0Hz,2H),0.96(t,J=7.0Hz,6H).
EXAMPLE 3 preparation of Compound 6
1. Synthesis of intermediate i-6
4-methylpyridine solution (0.4g, 1.5eq), glacial acetic acid (10mL) with 40% formaldehyde content (0.54g, 2eq) were added to an eggplant type bottle in sequence, stirred at room temperature for 1 hour, then intermediate h (1.2g, 1eq) was added to the eggplant type bottle, stirred at room temperature, and the reaction was detected by TLC to be complete. Then, part of the solvent is removed by rotary evaporation, 100mL of tap water is added, and a filter cake is filtered to obtain a product intermediate i-6, 0.73g, with the yield of 46%.
LC-MS(ESI):m/z 469.26(M+H)+
2. Synthesis of intermediate j-6
Intermediate i-6(570mg, 1eq) was dissolved in dichloromethane solution, then trifluoroacetic acid (2080mg, 15eq) was added for 3h, and the reaction was complete by TLC. Adding sodium bicarbonate into the reaction solution to adjust the pH value to 10, extracting, washing 3 times with ethyl acetate, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain a product intermediate j-6, wherein the yield of 125mg is 28%.
LC-MS(ESI):m/z 369.2(M+H)+
3. Synthesis of Compound 6
C-1(48mg, 1.2eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (56mg, 2eq) and j-6(60mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 6, wherein the yield of 30mg is 48%.
LC-MS(ESI):m/z 576.3(M+H)+
1H NMR(600MHz,CDCl3)δ9.39(s,1H),8.73(s,1H),8.41(d,J=5.2Hz,1H),8.10(d,J=6.9Hz,1H),7.83(s,1H),7.40(d,J=7.4Hz,1H),7.31–7.27(m,2H),7.24(d,J=5.2Hz,2H),6.72(d,J=32.0Hz,2H),6.26(dt,J=17.2,13.5Hz,4H),5.66(d,J=9.8Hz,1H),3.96(s,3H),3.88(s,3H),3.32(s,2H),2.03–1.64(m,8H),1.41(s,1H),0.91(d,J=5.6Hz,3H).
EXAMPLE 4 preparation of Compound 7
1. Synthesis of intermediate c-2
Compound a (432mg, 1.1eq), b-2(600mg, 1.1eq), and aluminum trichloride (382.4mg, 1eq) were added to a 50mL eggplant-shaped flask, reacted at 80 deg.C, the reaction was complete by TLC, ice water was added, the mixture was stirred for 5min, filtered with suction, and the cake was rinsed with 50mL of water. Column chromatography separation to obtain intermediate c-2 with a yield of 400mg 46%.
LC-MS(ESI):m/z 295.07(M+H)+
2. Synthesis of Compound 7
C-2(50mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (53mg, 2eq) and j-4(50mg, 1.1eq) were added thereto, nitrogen gas was introduced, reaction was carried out at 60 ℃ and completion of the reaction was detected by TLC. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 7, wherein the yield of 30mg is 30%.
LC-MS(ESI):m/z 615.2(M+H)+
1H NMR(600MHz,CDCl3)δ9.49(s,1H),9.18(s,1H),9.04(d,J=2.3Hz,1H),8.56(d,J=6.9Hz,1H),8.22(s,1H),7.89(s,1H),7.45(d,J=8.2Hz,1H),7.35(t,J=7.5Hz,1H),7.26(s,1H),7.26–7.22(m,2H),6.75(d,J=10.8Hz,2H),6.32–6.15(m,4H),5.67(d,J=10.2Hz,1H),3.99(s,3H),3.90(s,3H),3.69(d,J=27.1Hz,4H),3.29(d,J=12.9Hz,1H),3.16(d,J=13.3Hz,1H),2.69(s,2H),2.36(s,2H).
EXAMPLE 5 preparation of Compound 8
1. Synthesis of Compound 8
C-2(94mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (100mg, 2eq) and j-5(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 8, wherein the yield of 30mg is 17%.
LC-MS(ESI):m/z 601.3(M+H)+
1H NMR(600MHz,DMSO)δ10.19(s,1H),8.99(s,1H),8.84–8.71(m,2H),8.53(s,1H),8.35(s,2H),7.62(d,J=8.2Hz,1H),7.44(s,1H),7.30(dt,J=38.8,7.2Hz,3H),6.89(s,1H),6.57(s,1H),6.28(d,J=41.4Hz,2H),6.10(d,J=17.0Hz,1H),5.72(s,1H),4.00(d,J=23.6Hz,6H),3.08(s,2H),2.96(s,2H),1.27–0.79(m,8H).
EXAMPLE 6 preparation of Compound 9
1. Synthesis of intermediate i-9
Piperazine mesylate (1.5eq), 40% formaldehyde (270mg, 1.5eq) glacial acetic acid (10mL) were added sequentially to an eggplant type bottle and stirred at room temperature for 1 hour, then intermediate h (2g, 1eq) was added to the eggplant type bottle and stirred at room temperature, and the reaction was detected by TLC. And (4) evaporating part of the solvent, adding 100mL of tap water, and filtering a filter cake to obtain a product intermediate i-9.
LC-MS(ESI):m/z 534.2(M+H)+
2. Synthesis of intermediate j-9
Intermediate i-9(500mg, 1eq) was dissolved in dichloromethane solution, then trifluoroacetic acid (1600mg, 15eq) was added for 3h and the reaction was complete by TLC. Adding sodium bicarbonate into the reaction solution to adjust the pH value to 10, extracting, washing with ethyl acetate for 3 times, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain a product intermediate j-9, wherein the yield of 160mg is 40%.
LC-MS(ESI):m/z 434.18(M+H)+
3. Synthesis of Compound 9
C-2(60mg, 1.2eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (48mg, 2eq) and j-9(60mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and was detected by TLC to be complete. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 9, wherein the yield of 15mg is 15%.
LC-MS(ESI):m/z 692.3(M+H)+
1H NMR(600MHz,DMSO)δ9.36(s,1H),8.96(d,J=2.5Hz,1H),8.76–8.68(m,2H),8.53(s,1H),8.35–8.29(m,2H),7.61(d,J=8.1Hz,1H),7.41(dd,J=8.0,4.3Hz,1H),7.33(t,J=7.5Hz,1H),7.26(t,J=7.3Hz,1H),7.14(s,1H),6.75(s,1H),6.29(dd,J=17.0,10.3Hz,1H),6.13(s,2H),6.10(d,J=17.5Hz,1H),5.68(d,J=10.5Hz,1H),3.97(s,3H),3.93(d,J=9.8Hz,3H),3.04(s,4H),2.85(s,2H),2.42(s,4H),1.23(s,3H).
EXAMPLE 7 preparation of Compound 10
1. Synthesis of intermediate j-10
Intermediate h (1000mg, 1eq) was dissolved in dichloromethane solution, then trifluoroacetic acid (4790mg, 15eq) was added for 3h and the reaction was complete by TLC. Then adding sodium bicarbonate into the reaction liquid to adjust the pH value to 10, washing the reaction liquid for 3 times by ethyl acetate, extracting, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain a product intermediate j-10, wherein the yield of 800mg is 90%.
LC-MS(ESI):m/z 258.1M+H)+
2. Synthesis of Compound 10
C-1(113mg, 1.2eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (140mg, 2eq) and j-10(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and was detected by TLC to be complete. Adding sodium bicarbonate into the reaction solution, adjusting the pH value to 10, extracting, washing twice with dichloromethane, combining organic phases, performing reduced pressure spin drying, and performing column chromatography separation to obtain the compound 10, wherein the yield of 50mg is 23%.
LC-MS(ESI):m/z 465.2M+H)+
1H NMR(600MHz,DMSO)δ9.16(s,1H),8.46(d,J=8.0Hz,1H),8.39(d,J=5.4Hz,1H),8.36(s,1H),8.33(s,1H),8.08(s,1H),7.54(d,J=8.2Hz,1H),7.30(d,J=5.4Hz,1H),7.27(t,J=7.2Hz,1H),7.19(t,J=7.3Hz,1H),7.15(s,1H),6.74(s,1H),6.09(t,J=3.1Hz,1H),5.97(d,J=1.4Hz,1H),3.97(s,3H),3.89(s,3H),3.09(dt,J=15.5,9.8Hz,1H),2.79(dd,J=15.2,9.6Hz,1H),2.67(dt,J=12.7,9.7Hz,1H),2.26(t,J=11.2Hz,1H).
EXAMPLE 8 preparation of Compound 11
1. Synthesis of intermediate c-3
The compound a (1000mg, 1eq), b-3(1370mg, 1.1eq), and aluminum trichloride (1000mg, 1eq) were added to a 50mL eggplant-shaped flask, reacted at 80 deg.C, the reaction was detected by TLC to be complete, then ice water was added, stirred for 5min, filtered with suction, and the cake was washed with 50mL of water. Column chromatography separation to obtain intermediate c-3 with 400mg yield of 18%.
LC-MS(ESI):m/z 294.1(M+H)+
2. Synthesis of Compound 11
C-3(94mg, 1.2eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (100mg, 2eq) and j-5(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Sodium bicarbonate was added to the reaction mixture, pH was adjusted to 10, dichloromethane was washed twice, the organic phases were combined, spin-dried under reduced pressure, and column chromatography was performed to obtain compound 11 in a yield of 30mg of 17%.
LC-MS(ESI):m/z 600.3M+H)+
1H NMR(600MHz,DMSO)δ10.19(s,1H),8.99(s,2H),8.84–8.71(m,2H),8.53(s,1H),8.35(s,2H),7.62(d,J=8.2Hz,1H),7.44(s,1H),7.30(dt,J=38.8,7.2Hz,3H),6.89(s,1H),6.57(s,1H),6.28(d,J=41.4Hz,2H),6.10(d,J=17.0Hz,1H),5.72(s,1H),4.24(dd,J=214.8,34.7Hz,2H),4.00(d,J=23.6Hz,6H),3.08(s,2H),2.96(s,1H),1.20(d,J=34.6Hz,3H),0.92–0.84(m,3H).
EXAMPLE 9 preparation of Compound 12
1. Synthesis of intermediate i-12
Dimethylamine solution (0.315g, 1.5eq), glacial acetic acid (10mL) with 40% formaldehyde content (0.315g, 1.5eq) were added to the eggplant type bottle in sequence, stirred at room temperature for 1 hour, then intermediate h (1000mg, 1eq) was added to the eggplant type bottle, stirred at room temperature, and the reaction was detected by TLC to be complete. Then, part of the solvent is removed by rotary evaporation, 100mL of tap water is added, and a filter cake is filtered to obtain a product intermediate i-12.
LC-MS(ESI):m/z 415.2(M+H)+
2. Synthesis of intermediate j-12
Intermediate i-12(500mg, 1eq) was dissolved in dichloromethane and trifluoroacetic acid (2060mg, 15eq) was added for 3h, and the reaction was complete as checked by TLC. Then adding sodium bicarbonate into the reaction liquid to adjust the pH value to 10, extracting, washing 3 times by ethyl acetate, combining organic phases, carrying out decompression spin-drying, and carrying out column chromatography separation to obtain a product intermediate j-12, wherein the recovery rate of 200mg is 52%.
LC-MS(ESI):m/z 315.2(M+H)+
3. Synthesis of Compound 12
C-3(102mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (109mg, 2eq) and j-12(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Then adding sodium bicarbonate to adjust the pH value to 10, extracting, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain the compound 12, wherein the recovery rate of 30mg is 17%.
LC-MS(ESI):m/z 572.27M+H)+
1H NMR(600MHz,DMSO)δ10.79(s,1H),9.00(s,1H),8.36(d,J=8.2Hz,1H),8.29(s,1H),8.23(d,J=7.9Hz,1H),8.19(s,1H),7.83(t,J=7.6Hz,1H),7.68(d,J=8.4Hz,1H),7.60(d,J=8.2Hz,1H),7.43(t,J=7.5Hz,1H),7.31(t,J=7.6Hz,1H),7.24(t,J=7.4Hz,1H),7.03(s,1H),6.80(s,1H),6.15(t,J=17.7Hz,4H),5.73–5.64(m,1H),3.97(s,3H),3.95(d,J=11.6Hz,3H),2.49–2.14(m,6H),1.23(s,2H).
EXAMPLE 10 preparation of Compound 13
1. Synthesis of Compound 13
After c-1(60mg, 1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (48mg, 2eq) and j-9(40mg, 1.2eq) were added thereto, and the reaction was purged with nitrogen at 60 ℃ and checked by TLC to be complete. Then adding sodium bicarbonate to adjust the pH value to 10, extracting, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain the compound 13, wherein the recovery rate of 22mg is 35%.
LC-MS(ESI):m/z 641.26M+H)+
1H NMR(600MHz,CDCl3)δ9.63(s,1H),8.80(s,1H),8.43(d,J=4.6Hz,1H),8.11(s,1H),7.99(s,1H),7.85(s,1H),7.40(d,J=7.0Hz,1H),7.29(dd,J=13.9,7.0Hz,3H),6.75(d,J=8.0Hz,2H),6.29(s,1H),6.25(s,2H),6.11–6.02(m,1H),5.67(d,J=10.4Hz,1H),3.96(s,3H),3.90(s,3H),3.11(d,J=23.2Hz,4H),2.69(s,4H),2.37(s,2H),1.26(d,J=10.5Hz,3H).
EXAMPLE 11 preparation of Compound 14
1. Synthesis of Compound 14
C-1(85mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (109mg, 2eq) and j-12(100mg, 1eq) were added thereto, nitrogen gas was introduced, reaction was carried out at 60 ℃ and completion of the reaction was detected by TLC. Then adding sodium bicarbonate to adjust the pH value to 10, extracting, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain a product 14, wherein the recovery rate of 30mg is 18%.
LC-MS(ESI):m/z 522.25(M+H)+
1H NMR(600MHz,DMSO)δ11.02(s,1H),8.80(s,1H),8.49(s,1H),8.40(d,J=5.3Hz,1H),8.35(d,J=7.5Hz,1H),8.02(s,1H),7.54(d,J=8.1Hz,1H),7.32(d,J=5.3Hz,1H),7.26(t,J=7.5Hz,1H),7.20(t,J=7.4Hz,1H),6.96(s,1H),6.79(s,1H),6.17(s,2H),6.14(d,J=5.5Hz,2H),5.72–5.66(m,1H),3.90(s,3H),3.90(s,3H),2.24(s,6H),1.23(s,2H).
EXAMPLE 12 preparation of Compound 15
1. Synthesis of intermediate i-15
The pyrrolidine solution (1g, 1.5eq) and glacial acetic acid (10mL) with 40% formaldehyde content (0.315g, 1.5eq) were added to an eggplant-shaped bottle in sequence and stirred at normal temperature for 1 hour, and then the intermediate h (1g, 1eq) was added to the eggplant-shaped bottle and stirred at normal temperature, and the reaction was detected to be complete by TLC. And (4) evaporating part of the solvent, adding 100mL of tap water, and filtering a filter cake to obtain a product intermediate i-15.
LC-MS(ESI):m/z 441.24(M+H)+
2. Synthesis of intermediate j-15
Intermediate i-15(600mg, 1eq) was dissolved in dichloromethane solution, followed by trifluoroacetic acid (2330mg, 15eq) for 3h with TLC check complete. Then sodium bicarbonate is added into the reaction liquid to adjust the pH value to 10, ethyl acetate is used for washing for 3 times, organic phases are combined, decompression and spin-drying are carried out, and column chromatography separation is carried out to obtain a product intermediate j-15 with the yield of 86 percent and the product intermediate j-15 with the yield of 400 mg.
LC-MS(ESI):m/z 341.19(M+H)+
3. Synthesis of Compound 15
C-1(100mg, 1.5eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (128mg, 2eq) and j-15(127mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and was detected by TLC to be complete. Then adding sodium bicarbonate to adjust the pH value to 10, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain the compound 15 with 30mg yield of 19%.
LC-MS(ESI):m/z 548.27(M+H)+
1H NMR(600MHz,DMSO)δ10.65(d,J=51.5Hz,1H),8.80(d,J=19.4Hz,1H),8.47(d,J=24.1Hz,1H),8.40(d,J=5.3Hz,1H),8.35(t,J=8.2Hz,1H),8.02(s,1H),7.54(d,J=8.2Hz,1H),7.32(t,J=7.1Hz,1H),7.26(t,J=7.5Hz,1H),7.19(t,J=7.4Hz,1H),7.02(s,1H),6.75(s,1H),6.17(s,1H),6.15(d,J=2.6Hz,1H),6.14–6.10(m,2H),5.70(dd,J=7.7,4.3Hz,1H),3.90(s,6H),3.37(s,2H),2.52(d,J=15.8Hz,4H),1.76(s,4H).
EXAMPLE 13 preparation of Compound 16
1. Synthesis of Compound 16
C-2(102mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (109mg, 2eq) and j-12(90mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and was detected by TLC to be complete. Then sodium bicarbonate is added to adjust the pH value to 10, dichloromethane is used for washing twice, organic phases are combined, decompression and spin-drying are carried out, and column chromatography separation is carried out to obtain 16, 30mg and 19% yield.
LC-MS(ESI):m/z 573.26(M+H)+
1H NMR(600MHz,DMSO)δ10.98(s,1H),8.97(dd,J=4.2,1.8Hz,1H),8.77(s,1H),8.73(dd,J=8.2,1.7Hz,1H),8.52(s,1H),8.34(s,1H),8.30(d,J=7.2Hz,1H),7.61(t,J=6.4Hz,1H),7.41(dd,J=8.1,4.3Hz,1H),7.33(dd,J=9.0,5.3Hz,1H),7.26(q,J=7.4Hz,1H),7.03(s,1H),6.79(s,1H),6.16(d,J=3.1Hz,2H),6.13(d,J=8.4Hz,2H),5.69(dd,J=8.5,3.5Hz,1H),3.97(s,3H),3.92(s,3H),2.23(s,6H),1.23(s,2H).
EXAMPLE 14 preparation of Compound 17
1. Synthesis of Compound 17
C-3(137mg, 1.2eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (134mg, 2eq) and j-10(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and was detected by TLC to be complete. Then sodium bicarbonate is added to adjust the pH value to 10, dichloromethane is used for washing twice, organic phases are combined, decompression and spin-drying are carried out, and column chromatography separation is carried out to obtain the compound 17 with the yield of 30mg and 15%.
LC-MS(ESI):m/z 515.26(M+H)+
1H NMR(600MHz,DMSO)δ10.79(s,1H),9.00(s,1H),8.36(d,J=8.2Hz,1H),8.29(s,1H),8.23(d,J=7.9Hz,1H),8.19(s,1H),7.83(t,J=7.6Hz,1H),7.68(d,J=8.4Hz,1H),7.60(d,J=8.2Hz,1H),7.43(t,J=7.5Hz,1H),7.31(t,J=7.6Hz,1H),7.24(t,J=7.4Hz,1H),7.03(s,1H),6.80(s,1H),6.15(t,J=17.7Hz,4H),5.73–5.64(m,1H),3.97(s,3H),3.95(d,J=11.6Hz,3H),2.49–2.14(m,6H),1.23(s,2H).
EXAMPLE 15 preparation of Compound 18
1. Synthesis of Compound 18
C-3(95mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (101mg, 2eq) and j-15(100mg, 1eq) were added thereto, nitrogen gas was introduced, and the reaction was carried out at 60 ℃ and checked by TLC to be complete. Then adding sodium bicarbonate to adjust the pH value to 10, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain the compound 18 with the yield of 30mg being 18%.
LC-MS(ESI):m/z 598.26(M+H)+
1H NMR(600MHz,DMSO)δ10.47(s,1H),8.97(s,1H),8.36(d,J=8.2Hz,1H),8.29(s,1H),8.24(d,J=7.9Hz,1H),8.19(s,1H),7.84(t,J=7.5Hz,1H),7.69(d,J=7.9Hz,1H),7.60(d,J=8.2Hz,1H),7.43(t,J=7.4Hz,1H),7.31(t,J=7.5Hz,1H),7.23(t,J=7.4Hz,1H),7.07(s,1H),6.77(s,1H),6.15(d,J=21.1Hz,4H),5.73–5.66(m,1H),3.97(s,3H),3.94(s,3H),2.50(s,4H),1.83(d,J=64.7Hz,4H),1.23(s,2H).
EXAMPLE 16 preparation of Compound 19
1. Synthesis of Compound 19
C-2(95mg, 1.1eq) was dissolved in 5mL of isopropanol, p-toluenesulfonic acid (101.3mg, 2eq) and j-15(100mg, 1eq) were added thereto, nitrogen gas was introduced, reaction was carried out at 60 ℃ and completion of the reaction was detected by TLC. Then adding sodium bicarbonate to adjust the pH value to 10, washing twice by dichloromethane, combining organic phases, carrying out reduced pressure spin-drying, and carrying out column chromatography separation to obtain a compound 19, wherein the recovery rate of 30mg is 17%.
LC-MS(ESI):m/z 599.26(M+H)+
1H NMR(600MHz,DMSO)δ10.74(d,J=88.1Hz,1H),8.98(d,J=2.5Hz,1H),8.75(d,J=6.6Hz,2H),8.51(s,1H),8.35(s,1H),8.32(d,J=7.2Hz,1H),7.61(t,J=7.3Hz,1H),7.43(dd,J=8.0,4.2Hz,1H),7.38–7.31(m,1H),7.27(d,J=7.1Hz,1H),6.78(s,1H),6.59(s,1H),6.31(s,1H),6.13(t,J=28.0Hz,3H),5.68(d,J=10.9Hz,1H),3.97(d,J=9.2Hz,6H),2.51(s,4H),1.87(d,J=45.3Hz,4H),1.27–1.12(m,2H).
EXAMPLE 17 Compound 4-19 in vitro cell proliferation inhibition assay
1. The compounds 4 to 19 provided in examples 1 to 16 were used as test samples, and showed excellent antitumor effects.
(1) Half maximal Inhibitory Concentration (IC) of Compounds 4 to 19 against tumor cells50) The determination method comprises the following steps:
① collecting H1975, A549 cells in logarithmic phase, preparing cell suspension with RPMI1640 medium, inoculating the cells into 96-well cell culture plate at 100 μ L/well, and culturing at 37 deg.C with 5% CO2Culturing in an incubator for 24 hours;
② treating cells with compound according to 6 concentration gradient, 100 μ L/well, adding solvent control group and blank control group, each group having 3 multiple wells (removing original culture medium before administration, adding medicinal liquid), and treating at 37 deg.C with 5% CO2Culturing in an incubator for 48 hours;
③ observing cell state under inverted microscope, adding 20 μ L MTT solution into each well, and incubating for 4 h;
④ at room temperature at 1000rpm for 10min, carefully discarding the supernatant, air-drying in a superclean bench, adding DMSO to dissolve the formazan, and dissolving the formazan at 150 μ L/well.
⑤ shaking on shaking table for 5min to dissolve purple crystal, standing for 10min, measuring OD value of each well at 490nm wavelength of enzyme labeling instrument, recording result, and calculating survival rate of each concentration treatment group.
Survival rate was OD490 drug treated/OD 490 vehicle control; inhibition rate 1-survival rate
(2) Experimental data were analyzed using SPSS statistical software.
2. The results of the inhibition of H1975 and A549 activities of the compounds are shown in Table 1 by taking AZD9291 as a positive control result.
Table 1 results of in vitro bioactivity test of compounds
Claims (9)
1. Pyrimidines, pyrido [2,3-d ] pyrimidines, quinazolines and pharmaceutically acceptable salts, prodrugs or solvates thereof of the general formula (I):
wherein,
R1is composed ofWherein X is selected from one of F, Cl, Br, OH or CN;
R2is composed ofAny one of the above;
R3is any one of hydrogen or oxygen substituted C1-C6 alkyl, CD3 or F substituted C1-C6 alkyl;
R4comprises the following steps:
2. the pyrimidines, pyrido [2,3-d ] pyrimidines, quinazolines, and pharmaceutically acceptable salts, prodrugs, or solvates thereof of claim 1, having the following structural formula:
。
3. a composition comprising the pyrimidine, pyrido [2,3-d ] pyrimidine, quinazoline compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof as an active ingredient, in combination with a pharmaceutically acceptable carrier.
4. The composition of claim 3, wherein the pharmaceutically acceptable carrier is selected from one or more of a filler, a disintegrant, a binder, and a lubricant.
5. The composition of claim 3, wherein the composition is formulated into a tablet, capsule, granule, spray or injection.
6. A pyrimidine, pyrido [2,3-d ] pyrimidine, quinazoline compound as defined in claim 1 or 2, and a pharmaceutically acceptable salt, prodrug or solvate thereof and a use of a composition as defined in claim 3 or 4 or 5 as a protein tyrosine kinase inhibitor.
7. The use according to claim 6, wherein the protein tyrosine kinase inhibitor is an epidermal growth factor receptor inhibitor.
8. Use of a pyrimidine, pyrido [2,3-d ] pyrimidine, quinazoline compound according to claim 1 or 2, a pharmaceutically acceptable salt, prodrug or solvate thereof, and a composition according to claim 3 or 4 or 5 for the preparation of a medicament for the treatment of a disease associated with overexpression of an epidermal growth factor receptor.
9. The use according to claim 8, wherein the diseases associated with the overexpression of the EGF are selected from renal cancer, lung cancer, prostate cancer, pancreatic cancer, breast cancer and glioma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910613192.6A CN110283162B (en) | 2019-07-09 | 2019-07-09 | Epidermal growth factor receptor inhibitor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910613192.6A CN110283162B (en) | 2019-07-09 | 2019-07-09 | Epidermal growth factor receptor inhibitor and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110283162A true CN110283162A (en) | 2019-09-27 |
CN110283162B CN110283162B (en) | 2022-04-05 |
Family
ID=68021971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910613192.6A Active CN110283162B (en) | 2019-07-09 | 2019-07-09 | Epidermal growth factor receptor inhibitor and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110283162B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805304A (en) * | 2022-04-19 | 2022-07-29 | 辽宁大学 | 4-methoxyphenyl-1, 3-diamine derivatives containing 1-methyl-1H-indole structure and application thereof |
CN115819406A (en) * | 2023-02-24 | 2023-03-21 | 淄博百极荣创医药科技有限公司 | Synthetic method of 3- (4-pyrimidine) -1H-indole compound |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN106496196A (en) * | 2016-10-20 | 2017-03-15 | 南京雷科星生物技术有限公司 | Or a kind of quinazoline, Pyridopyrimidine be double and pyrimidine derivatives egf inhibitor and preparation method thereof and purposes |
CN106559991A (en) * | 2014-06-19 | 2017-04-05 | 阿里亚德医药股份有限公司 | For the heteroaryl compound of kinase inhibition |
CN107382879A (en) * | 2016-06-21 | 2017-11-24 | 郑州泰基鸿诺医药股份有限公司 | A kind of pyrimidines, EGFR inhibitor and its application |
CN108069939A (en) * | 2016-11-16 | 2018-05-25 | 中国科学院上海药物研究所 | Compound, its preparation method, pharmaceutical composition and purposes containing conjugation connection acrylamide structure |
CN108191861A (en) * | 2018-03-01 | 2018-06-22 | 天津大学 | N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls]-trans- -2,4- Pentadienamides |
CN108558865A (en) * | 2018-04-04 | 2018-09-21 | 辽宁大学 | One kind is using pyrido [2,3-d] pyrimidine structure as derivative of parent nucleus and its preparation method and application |
-
2019
- 2019-07-09 CN CN201910613192.6A patent/CN110283162B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN106559991A (en) * | 2014-06-19 | 2017-04-05 | 阿里亚德医药股份有限公司 | For the heteroaryl compound of kinase inhibition |
CN107382879A (en) * | 2016-06-21 | 2017-11-24 | 郑州泰基鸿诺医药股份有限公司 | A kind of pyrimidines, EGFR inhibitor and its application |
CN106496196A (en) * | 2016-10-20 | 2017-03-15 | 南京雷科星生物技术有限公司 | Or a kind of quinazoline, Pyridopyrimidine be double and pyrimidine derivatives egf inhibitor and preparation method thereof and purposes |
CN108069939A (en) * | 2016-11-16 | 2018-05-25 | 中国科学院上海药物研究所 | Compound, its preparation method, pharmaceutical composition and purposes containing conjugation connection acrylamide structure |
CN108191861A (en) * | 2018-03-01 | 2018-06-22 | 天津大学 | N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls]-trans- -2,4- Pentadienamides |
CN108558865A (en) * | 2018-04-04 | 2018-09-21 | 辽宁大学 | One kind is using pyrido [2,3-d] pyrimidine structure as derivative of parent nucleus and its preparation method and application |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805304A (en) * | 2022-04-19 | 2022-07-29 | 辽宁大学 | 4-methoxyphenyl-1, 3-diamine derivatives containing 1-methyl-1H-indole structure and application thereof |
CN114805304B (en) * | 2022-04-19 | 2024-05-31 | 辽宁大学 | 4-Methoxyphenyl-1, 3-diamine derivative containing 1-methyl-1H-indole structure and application thereof |
CN115819406A (en) * | 2023-02-24 | 2023-03-21 | 淄博百极荣创医药科技有限公司 | Synthetic method of 3- (4-pyrimidine) -1H-indole compound |
Also Published As
Publication number | Publication date |
---|---|
CN110283162B (en) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3216786B1 (en) | Pyrimidine compounds, preparation method therefor and pharmaceutical uses thereof | |
CN107840846B (en) | Pyrimidine ring-containing compound, EGFR inhibitor and application thereof | |
CN113527335A (en) | Macrocyclic compound as EGFR inhibitor and application thereof | |
CN105254615B (en) | Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers | |
CN114656482A (en) | Macrocyclic heterocyclic compound as EGFR inhibitor and application thereof | |
CN107531678B (en) | EGFR inhibitor and pharmaceutically acceptable salts and polymorphs thereof and uses thereof | |
US10882845B2 (en) | Crystal form of deuterated AZD9291, preparation method therefor, and use thereof | |
CN110483485A (en) | Pyrimidines, preparation method and medical usage | |
CN108558865B (en) | Derivative taking pyrido [2,3-d ] pyrimidine structure as mother nucleus, and preparation method and application thereof | |
CN110283162B (en) | Epidermal growth factor receptor inhibitor and application thereof | |
CN113773305B (en) | Aminopyrimidine derivative and application thereof as EGFR tyrosine kinase inhibitor | |
CN116096372B (en) | EGFR inhibitor, preparation method and pharmaceutical application thereof | |
CN112174940A (en) | 3- (6, 7-bis (2-methoxyethoxy) -quinazoline-4-amido) phenyl-1H-triazole derivative | |
CA2956773C (en) | Deuterated quinazolinone compounds and pharmaceutical compositions comprising same | |
CN113861195B (en) | Multi-condensed-ring EGFR inhibitor as well as preparation method and application thereof | |
CN112010789A (en) | Vinyl sulfonamide or vinyl amide compounds, and preparation method and application thereof | |
CN111718325A (en) | 2,4, 5-substituted pyrimidine compound and preparation method and application thereof | |
CN115433207A (en) | Macrocyclic heterocyclic compound as EGFR inhibitor and application thereof | |
CN115803325A (en) | EGFR inhibitor and preparation method and application thereof | |
CN109438279B (en) | Small molecule compound for overcoming EGFR drug-resistant mutation and preparation method and application thereof | |
CN112279863A (en) | Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof | |
CN103601722B (en) | New antitumoral compounds | |
CN105566307B (en) | The indoles and naphthalene ketone derivant, preparation method, medical composition and its use that heterocycle replaces | |
EP3008071B1 (en) | Polymorphic form of icotinib and uses thereof | |
CN113248496B (en) | Pyrrolopyridine compound, salt thereof and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |